Veronique de Jager

Increased bactericidal activity but dose-limiting intolerability at 50 mg·kg⁻¹rifampicin

Lindsey H. M. te Brake, Veronique de Jager, Kim Narunsky et al. · European Respiratory Journal · 2021 · 60 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +16

A first-in-class leucyl-tRNA synthetase inhibitor, ganfeborole, for rifampicin-susceptible tuberculosis: a phase 2a open-label, randomized trial

Andreas H. Diacon, Clifton E. Barry, Alex Carlton et al. · Nature Medicine · 2024 · 49 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Fourteen-day PET/CT imaging to monitor drug combination activity in treated individuals with tuberculosis

Yingda L. Xie, Veronique de Jager, Ray Y. Chen et al. · Science Translational Medicine · 2021 · 47 citations · Full text

Medicine, Nuclear Medicine, Radiology +15

Fourteen-Day Bactericidal Activity, Safety, and Pharmacokinetics of Linezolid in Adults with Drug-Sensitive Pulmonary Tuberculosis

Andreas H. Diacon, Veronique de Jager, Rodney Dawson et al. · Antimicrobial Agents and Chemotherapy · 2020 · 39 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17

Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial

Veronique de Jager, Nikhil Gupte, Sílvia Nunes et al. · American Journal of Respiratory and Critical Care Medicine · 2022 · 31 citations · Full text

Medicine, Infectious Diseases, Pharmacology +16